Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were bought at an average price of $5.02 per share, for a total transaction of $50,200.00. Following the completion of the transaction, the chief executive officer now directly owns 2,285,731 shares of the company's stock, valued at $11,474,369.62. This represents a 0.44 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.
Mihael Hristos Polymeropoulos also recently made the following trade(s):
- On Friday, February 28th, Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock. The stock was bought at an average price of $4.76 per share, with a total value of $47,600.00.
- On Tuesday, February 25th, Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock. The stock was purchased at an average price of $4.46 per share, with a total value of $44,600.00.
Vanda Pharmaceuticals Stock Up 6.7 %
Shares of NASDAQ:VNDA opened at $5.13 on Thursday. The firm has a 50 day moving average of $4.60 and a 200 day moving average of $4.79. The company has a market capitalization of $299.16 million, a price-to-earnings ratio of -16.03 and a beta of 0.74. Vanda Pharmaceuticals Inc. has a 52 week low of $3.71 and a 52 week high of $6.75.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The firm had revenue of $53.19 million for the quarter, compared to the consensus estimate of $51.00 million. On average, sell-side analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.
Institutional Investors Weigh In On Vanda Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in VNDA. GSA Capital Partners LLP purchased a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter worth about $143,000. Empowered Funds LLC boosted its stake in shares of Vanda Pharmaceuticals by 5.3% during the 3rd quarter. Empowered Funds LLC now owns 228,287 shares of the biopharmaceutical company's stock worth $1,071,000 after acquiring an additional 11,524 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Vanda Pharmaceuticals by 7.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 780,933 shares of the biopharmaceutical company's stock worth $3,663,000 after acquiring an additional 55,567 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter worth about $84,000. Finally, Massachusetts Financial Services Co. MA acquired a new position in shares of Vanda Pharmaceuticals during the 3rd quarter worth about $864,000. 88.14% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on VNDA shares. StockNews.com started coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. They issued a "hold" rating for the company. HC Wainwright boosted their price target on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a "buy" rating in a report on Tuesday, February 18th.
Check Out Our Latest Analysis on Vanda Pharmaceuticals
Vanda Pharmaceuticals Company Profile
(
Get Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
